Bank of America Securities analyst Craig Bijou reiterated a Sell rating on Integra Lifesciences (IART – Research Report) yesterday and set a price target of $21.00.
Craig Bijou has given his Sell rating due to a combination of factors affecting Integra Lifesciences. The company is facing ongoing supply chain challenges that are expected to impact its growth, particularly in the first quarter of 2025. Despite a slight beat in Q4 earnings per share, the revenue fell short of expectations, and the guidance for 2025 indicates only modest organic growth, which is below previous projections.
Additionally, the first quarter revenue guidance is significantly below market consensus, primarily due to unresolved shipping holds and production issues. The company’s full-year guidance also falls short of market expectations, with potential additional supply disruptions factored into their projections. These persistent supply issues and the conservative outlook under a new CEO contribute to the cautious stance on the stock, leading to the Sell rating.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IART in relation to earlier this year.